Key facts
- It has raised $60.0M across 1 recorded rounds; the latest was Later Stage VC ($60.0M) in Nov 2022.
- Notable investors include New Enterprise Associates, Cormorant Asset Management, Versant Ventures.
- Nexo Therapeutics has filed 4 Form Ds with the SEC since 2022, most recently Mar 2026 ($60.0M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Nexo Therapeutics
Funding rounds
1 roundsAbout Nexo Therapeutics
Developer of a molecule oncology platform designed to advance the development of small-molecule therapies for patients with limited treatment options. The company's platform combines the power of covalent ligand discovery and chemical biology to unlock a pipeline of novel oncology therapies directed against previously intractable targets, enabling medical professionals to provide new treatment options for cancer and other diseases
- Sector
- Healthcare
- HQ
- Littleton, CO, United States
- Founded
- 2022
- Employees
- 20
- Website
- nexotx.com/
- Ownership
- Privately Held (backing)
Nexo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nexo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nexo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.